1-(2-Ethoxyethyl)-2-(4-methyl-l-homopiperazinyl)benzimidazole difumarate (KB 2413) have been developed as a new antiallergic agent. We have already reported on the absorption and excretion of the radioactivity following the administration of "C-labelled KB-2413 (KB-2413-1"C) in rats and guinea pigs." The report has shown that KB-2413 is nearly completely absorbed from the intestinal tract, and that more than one-half the ad ministered dose of KB-2413-'"C is excreted into the feces in both animal species. However, little information is available on the tissue distribution of KB-2413 and/or its metabolites.
In the present study, the distribution of the radioactivity after single and multiple oral administrations of KB-2413-14C to rats was mainly investigated. This paper also described the excretion of radioactivity during and after the multiple oral administration.
Experimental
Labelled compound-14C-labelled KB-2413 was identical to that used previously."
Animals-Male
Wistar rats weighing about 220g (specific pathogen-free, Shizuoka Labolatory Animal Center) were used. The diet and environmental conditions were the same as those described previously." In case of a single oral administration, rats were fasted for 16h prior to dosing and for 4 h post dosing. The animals were not fasted before and during the experiments when a multiple oral administration was performed.
Administration
of the drug-The labelled KB-2413 was diluted with the non-labe
Iled KB-2413 and was prepared as a solution in deionized water. KB-2413-14C was admi nistered in a single oral dose of 1 mg/kg (50 pCi/kg) to determine the tissue concentration and at a dose 1.5 mg/kg (154 pCi/kg) when the whole-body autoradiography experiments were performed. During a multiple administration, the drug was given orally once a day at a daily dose of 1 mg/kg. The dose of radioactivity was 100 pCi/kg in the experiment for the daily plasma level measurement and for the whole-body autoradiography, and 50
pCi/kg in other experiments. All solutions were administered in an approximate volume of about 2. 5 ml/kg. The solution of KB-2413-14C was given orally by the stomach tube.
Distribution after single oral administration-The whole-body autoradiography and the measurement of tissue levels after single oral administration of KB-2413-14C to fasted rats were carried out as follows.
Whole-body autoradiography : Rats were sacrificed under anesthesia with ether at 0. 25, 2, 6 h and 2 d after single oral administration. Then the rats were immediately frozen by dry-ice acetone (-78°C). Sections (40 pm) were obtained with a PMV Cryo-Microtome (2250, LKB-Produkter AB) at about -25°C, and attached to SalotapeR (Hisamitsu Phar maceutical Co., Ltd.). The sections were dried in a freezer for a few days and were placed in contact with X-ray films (No. 150, Fuji Photo Film Co., Ltd.) for 4 weeks. Then, the rats were exsanguinated by cutting the inferior vena cava. After the liver was perfused with 20 ml of cold saline through the hepatic portal vein, each organ or tissue was immediately excised. Whole and aliquots of tissues or organs were exactly weighed and then dried over P2O5 in vacuo. Then each sample was combusted and the radioactivity was determined.
Multiple oral administration-After multiple oral daily administration of KB-2413 "C every 24 h for up to 14 d , the measurements of plasma levels, urinary and fecal excre tion and tissue levels and whole-body autoradiography were carried out as follows.
Plasma levels : In one group of rats, blood samples were collected from the tail vein 24h after daily administration and 2, 3 and 4 d after the last (14th) administration. In the other group of rats, blood samples were collected from the tail vein at 5, 15, 30 min, 1, 2, 4, 6, 9, 12 and 24 h after the 1 st, 7 th and 14 th administration. Plasma samples were prepared by centrifugation of the blood samples at 12,000 rpm for 5 min. Urinary and fecal excretion : Rats were kept individually in the metabolic cages, and urine and feces samples were separately collected at 24 h after the daily administration and 2, 3 and 4 d after the 14 th administration.
Tissue levels : The radioactivity in the tissues was measured at 1 and 4 d after the 1 st and 14th administration and 1 d after the 7th administration.
Whole-body autoradiography : One and 4 d after the 14 th administration, the whole body autoradiography was carried out.
Determination of the radioactivity-The radioactivity of each sample was measured according to the method described previously."
Calculations-KB-2413 was given as the difumarate salt, and concentrations in the plasma or tissues were expressed as ng equivalent of KB-2413 base per ml or g. The con cetrations of the radioactivity in erythrocytes was calculated according to the equation :
Cs=CP x (1-Ht) +Ca x Ht, where CB, CP and Ca are the concentrations of radioactivity in whole blood, plasma and erythrocytes, respectively, and He represents the hematocrit (assumed as 0.46). All data were tested for statistically significant differences using Stu dents' t-test in case of 2 groups, or F-test and Tukey's test in case of 3 groups. pancreas, stomach contents, urine, kidney, Harder's gland, salivary gland, lung and spleen was higher than that in the blood. The radioactivity in the eye ball, central nervous system (CNS) and fat was fairly low. At 2 h, the radioactivity was high in the intestinal conte nts, urine, liver and kidney. Heterogenous distribution of the radioactivity was noted in the liver. At 6 h, the radioactivity was detected in the intestinal contents, urine, liver and kidney. At 2 d, very low radioactivity was observed in the intestinal contents, liver and kidney.
Tissue levels : The tissue levels of the radioactivity and the percent distribution of the radioactivity in the tissue at 0.25, 2, 6, 24 h, 2, 8 and 20 d after single oral administration are summarized in Tables I and II , respectively. Because the stomach, duodenum and jeju num were not excised as a whole but as a part, the percentages of the radioactivity found in these tissues were not calculated. The maximum level of the radioactivity was observed at 0. 25 h after dosing in most tissues. At 0. 25 h, the intestine and liver had much higher levels of the radioactivity than those of the other tissues. About 20 % of the dose was found in the liver at this time, and the concentration of radioactivity in the pancreas, kidney and lung were relatively high. On the other hand, the brain level corresponded to 6 % of that of the plasma level. The radioactivity of each tissue was gradually decreased and was lower than 0.5 % of the dose 24 h after dosing. Total volume of the blood and total weight of the skin and muscle were assumed as 6.4, 18.0 and 45.4 % of the body weight, respectively. Each value represents the mean±S.D. of three animals or the mean of two animals. a) Time after administration. b) Less than two times of back ground. The time-course of the radioactivity in plasma after the 1 st, 7 th and 14 th administra tion and its pharmacokinetic parameters are shown in Fig. 3 and Table III , respectively.
The first plasma peaks were observed at 0. 5-1 h after the 1 st, 7th and 14 th administra tion and the second plasma peaks at 4-6 h in every case. The AUCs after the 7 th and 14 th administration were slightly larger than that after the 1 st administration . However, there was no significant difference in the AUCs after the 7 th and 14th administration .
Urinary and fecal excretion : The cumulative urinary and fecal excretions of the radi oactivity for 24 h after the daily administration and for 24 h intervals up to 4 d after the 14 th administration in rats are shown in Fig. 4 . By 24 h after the 1 st , 2 nd, 3 rd and 7 th administration, the percent of the radioactivity excreted both into urine and feces were 78 . 1 ±3.6, 84.1±0.9, 90.1±4.0 and 94.0±0.7, respectively. Thereafter, the cumulative excre tion into urine and feces seemed to increase slightly, and the urinary and fecal excretion Tables IV and V , respectively. At 1 d after the 1 st. 7 th and 14 th dose, the radioactivity was high in the liver, kidney and thyroid, and low in the brain, eye ball and muscle (Table IV) . The ratios of tissue-to-plasma level in the thyroid, liver and spleen at 1 d after the 7th and 14 th dose were more than 2 times higher than those after the 1 st dose. Similarly the ratios in the blood, liver, spleen, kidney and testis at 4 d after the 14 th dose were more than 2 times higher than those after the 1 st dose. The ratios at 1 d after the 14 th dose were not higher than those after the 7th dose in any tissues (Table V) .
Whole-body autoradiography : Fig. 5 shows the whole-body autoradiograms at 1 and 4 d after the 14 th administration. At 1 d, low radioactivity was observed in the liver, thyroid, kidney and intestinal contents, though the kidney is not shown in the figure. At after single oral administration of KB-2413-"C to fasted rats (Fig. 1 , Tables I, II) . The radioactivity found in the liver at that time was about 20% of the administered dose. We have previously reported that the biliary excretion was the major route of the excretion for orally administered KB-2413-14C in rats.' The marked concentration of the radioacti vity in the liver might be responsible for the biliary excretion.
Whole-body autoradiograms showed the heterogenous distribution of the radioactivity in the liver (Figs. 1, 5 ). There have been some reports on the similar phenomenon. 2-4)
In these reports, microautoradiography revealed that the heterogeneous pattern of distribu tion was due to the periportal ( 14C]dehyrocorydaline, '-"S-chlorpromazine) or central ([14C]aminotriazole) localization of the radioactive compound in the hepatic lobule. The refore, further examination of the heterogeneous distribution of KB-2413 by microautora diography seems to be necessary.
The radioactivity was low in the CNS, both after the single oral administration of KB-2413-14C to fasted rats (Fig. 1, Table 1 ) and after the multiple oral administration to non-fasted rats (Table IV) . This may be an advantageous characteristics for the antialle rgic agents from a point of view of the undesirable side effect on the CNS.
The ratios of tissue-to-plasma levels in several tissues, which were calculated at 1 d after the 1 st, 7 th and 14 th dose, increased up to 7 times, but they did not increase up to 14 times (Table V) . The values of the AUCo_24h after the 1 st, 7 th and 14 th dose indicated the steady state was reached at the 7th dose (Table III) . The daily plasma levels from the 7 th to 14th dose were approximately constant (Fig. 2) . The proportions of the urinary and fecal excretions were not altered by the multiple dose (Fig. 4) . The radioactivity excreted into both urine and feces was about 98% of the cumulative dose within 4 d after the 14th administration (Fig. 4) . At this time, the concetrations of the radioactivity in the tissues except the thyroid, spleen and kidney were lower than those at 1 d after the 1 st administration (Table IV) .
In the previous study, the elimination half-life in plasma (t1/2) estimated from 9 to 24 h after single oral administration of KB-2413-'"C to fasted rats at doses of 1, 4 and 8 mg/ kg was adout 10 h." In the present study, the t1/2 estimated from 9 to 24 h after the 1 st, 7 th and 14 th dose to non-fasted rats at doses of 1 mg/kg once a day were 7. 6, 5. 5 and 10.2 h, respectively (Table III) . These facts suggested that the elimination rate of the radioactivity within 24 h was not affected by both food and the number of doses.
We have previously reported that the Tmax and Cmax were 0.25 h and 46.3 ng/ml, respectively, and the percentage of the radioactivity excreted into both urine and feces was about 95 % of the dose by 24 h, after the single oral administration of KB-2413-'"C to fasted rats." In the present multiple administration study, the Tmax, Cmax and percent of excretion into both urine and feces were 1 h, 22. 8 ng/ml and about 78 % of the dose by 24 h after the 1 st dose to non-fasted rats, respectively (Table III, Fig. 4 ). These differe nces might be mainly due to the delay of absorption by the presence of the gastrointestinal contents.
